Litigation Details for In Re: National Prescription Opiate Litigation (N.D. Ohio 2022)

In Re: National Prescription Opiate Litigation (N.D. Ohio 2022)

Docket		Date Filed	2022-11-04
Court	District Court, N.D. Ohio	Date Terminated
Cause	28:1446 Petition for Removal- Personal Injury	Assigned To	Dan A. Polster
Jury Demand	Both	Referred To
Parties	DR. PAUL GOLDENHEIM; EDGE PHARMACY; MISSISSIPPI HOSPITAL ASSOCIATION; NORTH CAROLINA WHOLESALE DRUG COMPANY; STEVEN A HOLPER, M.D., PROFESSIONAL CORPORATION
Patents	4,850,305; 6,106,864; 6,200,604; 6,417,175; 6,488,963; 6,545,040; 6,602,911; 6,649,180; 6,667,050; 6,893,662; 6,906,055; 6,913,768; 6,958,326; 6,992,218; 7,030,149; 7,163,931; 7,192,938; 7,304,036; 7,320,969; 7,320,976; 7,371,727; 7,410,957; 7,419,973; 7,642,258; 7,645,459; 7,645,460; 7,704,947; 7,704,984; 7,718,634; 7,741,358; 7,745,409; 7,790,199; 7,803,838; 7,829,121; 7,834,020; 7,838,552; 7,851,482; 7,888,342; 7,947,739; 7,994,220; 8,008,338; 8,022,106; 8,022,228; 8,038,988; 8,058,291; 8,080,526; 8,101,593; 8,110,553; 8,133,890; 8,168,209; 8,173,708; 8,193,195; 8,207,215; 8,217,083; 8,236,804; 8,242,294; 8,246,989; 8,263,054; 8,273,795; 8,283,379; 8,293,794; 8,309,060; 8,309,122; 8,329,216; 8,329,752; 8,338,485; 8,338,486; 8,354,409; 8,362,085; 8,367,649; 8,377,982; 8,436,051; 8,461,140; 8,481,598; 8,486,972; 8,486,973; 8,541,466; 8,546,367; 8,580,858; 8,589,182; 8,598,233; 8,629,111; 8,632,760; 8,633,162; 8,642,556; 8,648,048; 8,653,058; 8,664,215; 8,673,921; 8,685,930; 8,748,425; 8,748,573; 8,758,733; 8,772,306; 8,802,628; 8,808,737; 8,808,741; 8,846,100; 8,865,937; 8,871,779; 8,883,770; 8,894,987; 8,894,988; 8,906,950; 8,906,962; 8,926,953; 8,933,030; 8,946,281; 8,986,715; 9,050,302; 9,060,976; 9,073,933; 9,173,857; 9,216,183; 9,226,931; 9,248,191; 9,399,012; 9,399,025; 9,486,426; 9,492,389; 9,492,391; 9,492,392; 9,492,393; 9,517,219; 9,522,155; 9,522,919; 9,579,270; 9,636,349; 9,708,371; 9,770,453; 9,907,801; 9,907,802; 9,949,986; 9,957,480; RE43,879
Attorneys	Brent M. Buckley; F. Scott Galt; James D. Johnson; Mark Jenkins Alderman; Thomas Dean Adams
Firms	Brent M. Buckley; Bullivant, Houser & Bailey - Portland; Gordon & Rees LLP; Jones Day Cleveland; Lamp Bartram Levy Trautwein & Perry
Link to Docket	External link to docket

Biologic Drugs cited in In Re: National Prescription Opiate Litigation

Details for In Re: National Prescription Opiate Litigation (N.D. Ohio 2022)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-06-21	1717	Exhibit s to Chalos Declaration	infringed U.S. Patent Nos. 6,028,222 ("the '222 patent") and 6,992,218 ("the '…concerning ten patents covering Inomax (i.e., five patents expiring in 2029 and five patents expiring in…in the five patents expiring in 2031 are patentable. '222 and '218 Patent Litigation:… such investigation. Patent/Antitrust Litigation Inomax Patent Litigation: Praxair Distribution…this group of patents and the PTAB ruled in July 2016 that one claim of this patent survived review	External link to document
2019-07-03	1812	Exhibit 16 - Chalos Dec.:MNK 2016 10Q	infringed U.S. Patent Nos. 6,028,222 ("the '222 patent") and 6,992,218 ("the '…concerning ten patents covering Inomax (i.e., five patents expiring in 2029 and five patents expiring in…in the five patents expiring in 2031 are patentable. '222 and '218 Patent Litigation:… such investigation. Patent/Antitrust Litigation Inomax Patent Litigation: Praxair Distribution…this group of patents and the PTAB ruled in July 2016 that one claim of this patent survived review	External link to document
2019-07-09	1823	Exhibits 1-37 [redacted] to the Egler Declaration	Warner Chilcott’s U.S. Patent No. 6,893,662, expiring in November 2021 (the “‘662 Patent”), is invalid and/…) U.S. Patent No. 5,541,170 (the “‘170 Patent”) and U.S. Patent No. 5,541,171 (the “‘171 Patent”), formulation…Chilcott’s U.S. Patent Nos. 7,645,459 (the “‘459 Patent”) and 7,645,460 (the “‘460 Patent”), two formulation…infringement of the ‘459 Patent and ‘460 Patent. On August 21, 2012, the United States Patent and Trademark Office…to the Company U.S. Patent No. 8,246,989 (the “‘989 Patent”), a formulation patent expiring in January	External link to document
2019-07-19	1930	Exhibit 7 - OxyContin Label	Purdue Pharma L.P. U.S. Patent Numbers 6,488,963; 7,129,248; 8,309,060; 8,808,741; 8,821,929…overdose, priorities are the reestablishment of a patent and protected airway and institution	External link to document
2019-07-26	2063	Exhibit 2 - Mallinckrodt Inc.s Amendment No. 2 to Annual Report	against us alleging that we infringed U.S. Patent Nos. 6,913,768, 8,846,100, and 9,173,857 following receipt…alleging that the Company infringed U.S. Patent Nos. 6,913,768, 8,846,100, and 9,173,857 following receipt…single patent, trademark or license or any group of patents, trademarks or licenses. Patent protection…, alleging patent infringement or other violations of intellectual property rights. Patent holders may… the Orange Book patents listed for the branded product. A successful claim of patent or other intellectual	External link to document
2019-08-12	2167	Amended complaint	273 Cherokee 9,957,480 37,743 264…Cherokee Nation territory” as the areas set by the patents of 1838 and 1846, as modified, and further describes… Nation territory” as “those described by the patents of 1838 and 1846 diminished only by the Treaty…boundaries of the Cherokee Nation as defined in the Patent of 1838 . . . .” See also Title 33, Ch. 1 § 3(… by the treaties of 1828, 1833 and 1835 and the Patent of 1838 . . . .”); Title 68, § 1353 (imposing	External link to document
2019-08-13	2230	Exhibit 5	(Method of Use – #6,200,604) Major 3039 BTP CA Efficacy -…PDUFA dates: Patent Expiration – 2019 Non-CA – 4Q07… void in the pain market • Purdue to regain the patent on OxyContin; renewed promotion is expected •… conversion (mg vs. mcg) • Patent on FENTORA through 2019 •	External link to document